Z. Du
Molecular Biology · with Lovly · 2018
A researcher in the Science corpus: 1 paper; trusts 5 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 27 citations into it
- Oncology — 27 citations into it
- Genetics — 10 citations into it
- Hematology — 6 citations into it
- Rheumatology — 6 citations into it
Whom Z. Du trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- Fyodor A. Kondrashov
- Joseph Schlessinger
- Gerard Manning
- Nicolas Stransky
- Brian J. Druker
- J. Kuriyan
- M. Heinrich
- Susan S. Taylor
- Doron Lipson
- Ethan G. Cerami
Who trusts Z. Du overall
Papers from Z. Du's perspective
Ordered by how strongly the researchers Z. Du trusts endorse each paper. Same corpus, a different order for every researcher.
- Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (New England Journal of Medicine)
- The conformational plasticity of protein kinases. (Cell)
- Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* (Journal of Biological Chemistry)
- Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. (Journal of Clinical Oncology)
- The Protein Kinase Complement of the Human Genome (Science)
- An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. (Molecules and Cells)
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- The landscape of kinase fusions in cancer (Nature Communications)
- RET, ROS1 and ALK fusions in lung cancer (Nature Medicine)
- Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization.
Their papers
- Mechanisms of receptor tyrosine kinase activation in cancer (2018) — 884 citations